Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 148

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 148
---
 officers
or partners, registered persons or affiliates or as otherwise permitted under FINRA Rule 5110(e)(2). Pursuant to FINRA Rule 5110(e)(2)(A)(iii),
the Placement Agent Warrants meet an exception to the lock-up restriction under Rule 5110(e)(1) because the Company meets the registration
requirements of SEC Registration Form F-3 as set forth below.

The Company is a foreign private issuer,
as such term is defined in Rule 405 under the Securities Act, that satisfies the eligibility requirements for use of Form F-3 as set forth
in General Instructions I.A. to Form F-3 for (i) having a class of securities registered pursuant to Section 12(b) of the Exchange Act
and having filed at least one annual report on Form 20-F with the SEC, (ii) having been subject to the requirements of Section 12 of the
Exchange Act and having timely filed all materials required to be filed by the SEC for at least 12 calendar months immediately prior to
filing of the registration statement of which this prospectus forms a part, and (iii) having filed with the SEC all required electronic
filings, including all Interactive Data Files required to be submitted. In addition, the Company, including its consolidated or unconsolidated
subsidiaries, has not failed to pay any dividend or sinking fund installment on preferred stock or on any rental on one or more long-term
leases, which defaults in the aggregate are material to the financial position of the Company on a consolidated basis.

| 85 |

Right of First Refusal

We have agreed to grant
the placement agent, for a period of nine (9) months from the closing of this offering, if the Company receives at least an
aggregate of $10.0 million in gross proceeds from this offering, the right of first refusal to act as sole managing underwriter,
sole book runner, sole placement agent, or sole sales agent, for any and all future public or private equity, equity-linked or debt
(excluding commercial bank debt, the exercise of existing warrants or pursuant to the terms of the ELOC) offerings for which the
Company retains the service of an underwriter, advisor, finder or other person or entity in connection with such offering during
such nine (9) month period of the Company, or any successor to or any subsidiary of the Company. The Company shall not offer to
retain any entity or person in connection with such offering on terms more favorable than